Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Effect of diuretic-based antihypertensive treatment on cardiovasculardisease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. To assess the effect of low-dose, diuretic-based antihypertensive treatment on major cardiovasculardisease (CVD) event rates in older, non-insulin-treated diabetic patients with isolated systolic hypertension (ISH), compared with nondiabetic patients.Double-blind, randomized (...) , nonfatal plus fatal stroke, nonfatal myocardial infarction (MI) and fatal coronary heart disease (CHD), major CHD events, and all-cause mortality.The SHEP antihypertensive drug regimen lowered BP of both diabetic and nondiabetic patients, with few adverse effects. For both diabetic and nondiabetic patients, all outcome rates were lower for participants randomized to the active treatment group than for those randomized to the placebo group. Thus, 5-year major CVD rate was lower by 34% for active
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovasculardisease. Observational studies suggest that people who consume more fruits and vegetables containing beta carotene have somewhat lower risks of cancer and cardiovasculardisease, and earlier basic research suggested plausible mechanisms. Because large randomized trials of long duration were necessary to test this hypothesis directly, we conducted a trial of beta carotene (...) assigned to receive beta carotene and 11,035 assigned to receive placebo, there were virtually no early or late differences in the overall incidence of malignant neoplasms or cardiovasculardisease, or in overall mortality. In the beta carotene group, 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as compared with 1293 in the placebo group (relative risk, 0.98; 95 percent confidence interval, 0.91 to 1.06). There were also no significant differences in the number of cases of lung
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovasculardisease. Lung cancer and cardiovasculardisease are major causes of death in the United States. It has been proposed that carotenoids and retinoids are agents that may prevent these disorders.We conducted a multicenter, randomized, double-blind, placebo-controlled primary prevention trial -- the Beta Carotene and Retinol Efficacy Trial -- involving a total of 18,314 smokers, former smokers, and workers (...) to 1.57; P=0.02), as compared with the placebo group. There were no statistically significant differences in the risks of other types of cancer. In the active-treatment group, the relative risk of death from any cause was 1.17 (95 percent confidence interval, 1.03 to 1.33); of death from lung cancer, 1.46 (95 percent confidence interval, 1.07 to 2.00); and of death from cardiovasculardisease, 1.26 (95 percent confidence interval, 0.99 to 1.61). On the basis of these findings, the randomized trial
Cost effectiveness and equity of a community based cardiovasculardisease prevention programme in Norsjo, Sweden Cost effectiveness and equity of a community based cardiovasculardisease prevention programme in Norsjo, Sweden Cost effectiveness and equity of a community based cardiovasculardisease prevention programme in Norsjo, Sweden Lindholm L, Rosen M, Weinehall L, Asplund K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Community based cardiovasculardisease prevention (educational) programme. Type of intervention Screening; Primary prevention; Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population was taken from a rural community in Northern Sweden with an 80
Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovasculardisease Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovasculardisease Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovasculardisease Verheugt F W Authors' objectives To assess the safety of combining oral anticoagulant and antiplatelet therapy. Searching EMBASE was searched from 1960 to 1994. [A: The search strategy was not defined. Only (...) studies made? The author does not state how the papers were selected for the review, or how many of the reviewers performed the selection. Assessment of study quality [A: All studies which combined oral anticoaguant and antiplatelet therapy were included, provided cardiovasculardisorders were treated]. The author does not state how the papers were assessed for validity, or how many of the reviewers performed the validity assessment. Data extraction The author does not state how the data were
Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovasculardisease, mental health and haemoglobinopathies Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovasculardisease, mental health and haemoglobinopathies Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovasculardisease, mental health and haemoglobinopathies NHS Centre for Reviews and Dissemination; Social (...) Policy Research Unit, University of York Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination; Social Policy Research Unit, University of York. Ethnicity and health: reviews of literature and guidance for purchasers in the areas of cardiovasculardisease, mental health and haemoglobinopathies. University
Cardiovasculardisease. The Thrombolysis in Myocardial Ischemia trial randomized patients with unstable angina or non-Q-wave myocardial infarction and found that thrombolytic therapy was not beneficial and may be harmful. Drug treatment of hypercholesterolemia improves survival in patients with established coronary artery disease.
The antioxidant vitamins and cardiovasculardisease: a critical review of epidemiologic and clinical trial data The antioxidant vitamins and cardiovasculardisease: a critical review of epidemiologic and clinical trial data The antioxidant vitamins and cardiovasculardisease: a critical review of epidemiologic and clinical trial data Jha P, Flather M, Lonn E, Farkouh M, Yusuf S Authors' objectives To review prospective epidemiological studies and randomised trials regarding the role (...) of antioxidant vitamins (vitamins E and C, and beta-carotene) in the prevention of cardiovasculardisease. Searching Scientific literature was searched for all epidemiological studies (prospective cohort, prospective nested case-control, retrospective case-control, or geographic correlations) and RCTs of antioxidants and cardiovasculardisease. Keywords used were 'vitamin E', 'vitamin C', 'beta-carotene', 'vitamins', 'antioxidants', 'coronary heart disease', 'cerebrovascular disease', 'peripheral vascular
Long-term mortality after 5-year multifactorial primary prevention of cardiovasculardiseases in middle-aged men. To investigate the long-term effects of multifactorial primary prevention of cardiovasculardiseases (CVD).The 5-year randomized, controlled trial was performed between 1974 and 1980. The subjects and their risk factors were reevaluated in 1985. Posttrial mortality follow-up was continued up to December 31, 1989.Institute of Occupational Health, Helsinki, Finland, and Second (...) . Multiple logistic regression analysis of treatments in the intervention group did not explain the 15-year excess cardiac mortality.These unexpected results may not question multifactorial prevention as such but do support the need for research on the selection and interaction(s) of methods used in the primary prevention of cardiovasculardiseases.
Cardiovasculardisease risk reduction for tenth graders. A multiple-factor school-based approach. All tenth graders in four senior high schools (N = 1447) from two school districts participated in a cardiovasculardisease risk-reduction trial. Within each district, one school was assigned at random to receive a special 20-session risk-reduction intervention and one school served as a control. At a two-month follow-up, risk factor knowledge scores were significantly greater for students (...) choose "heart-healthy" snack items. Beneficial treatment effects were observed for resting heart rate, body mass index, triceps skin fold thickness, and subscapular skin fold thickness. The results suggest that it is feasible to provide cardiovasculardisease risk-reduction training to a large segment of the population through school-based primary prevention approaches.
Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovasculardisease in patients over the age of 60. Results of the European Working Party on High Blood Pressure in the Elderly (EWPHE) trial have been analysed in relation to age, sex, blood pressure, and previous cardiovasculardisease. Cardiovascular mortality and the cardiovascular study-terminating events were significantly and independently related to treatment, age, cardiovascular (...) complications at randomisation, and systolic but not diastolic blood pressure. The benefits of treatment observed in the trial seemed to be independent of entry blood pressure and the presence or absence of cardiovascular complications at entry. There was some evidence that treatment effect decreases with advancing age. Little or no benefit from treatment could be demonstrated in patients over the age of 80 years, the great majority of whom were women.
Multifactorial primary prevention of cardiovasculardiseases in middle-aged men. Risk factor changes, incidence, and mortality. In a randomized five-year multifactorial primary prevention trial of vascular diseases, hyperlipidemias, hypertension, smoking, obesity, and abnormal glucose tolerance of the high-risk test group (n = 612 men) were treated with dietetic-hygienic measures and hypolipidemic (mainly probucol and clofibrate) and antihypertensive (mainly diuretics and beta-blockers) agents